-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Compass Therapeutics, Lowers Price Target to $0.9

Benzinga·11/10/2026 15:35:53
Listen to the news
Wedbush analyst Robert Driscoll maintains Compass Therapeutics (NASDAQ:CMPX) with a Neutral and lowers the price target from $1 to $0.9.